Compare Lockheed Martin Corporation (LMT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Moderna, Inc. — how do they compare? Lockheed Martin Corporation trades at $509.59 (market cap $117.22B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Lockheed Martin Corporation is the larger of the two by market cap, and Lockheed Martin Corporation pays a 2.72% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and Moderna, Inc. for 59 Days on average.
| LMT | MRNA | |
|---|---|---|
Market Cap | $117.22B | $78.65B |
Volume | 1,101,121 | 37,373,437 |
Sector | Industrials | Health |
52-Week High | $676.70 | $203.46 |
52-Week Low | $439.19 | $22.36 |
Typical Hold Time | 86 Days | 59 Days |
Enterprise Value | $133.96B | $74.80B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $507.89, up 1.74% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 EPS beat but missed in Q4 2025 and Q1 2026, with revenue growth from $71B in 2024 to $75B in 2025. Analyst consensus is strongly bullish with 59% buy ratings and a $635.33 price target, representing 25% upside. Recent news highlights dividend increases for 23 straight years and strategic AI partnerships through Skunk Works innovation.
LMT offers attractive valuation with P/E of 18.73 and strong defense contract backlog, though recent earnings misses and rising debt-to-asset ratio to 36.44% pose execution risks. The stock presents value opportunity amid sustained Pentagon spending, but investors should monitor contract performance and interest rate sensitivity given $19.63B long-term debt.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
